Wei-Ting Hwang

Mar 13, 2024 | nature.com | Stephen J. Bagley |Meghan T. Logun |Julie K. Jadlowsky |Fang Chen |MacLean P. Nasrallah |Wei-Ting Hwang | +5 more

AbstractRecurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study’s primary endpoints were safety and determination of the maximum tolerated dose.